MikesLM, thank you the response. I read the Veritas report, which as you say is now mostly old news.
As you point out the Petra report is no longer up, perhaps the company will grant access directly.
Looking positive for the short to medium term especially with Remplir approvals pending in Asia and USA.
One query I have is around the portability of OrthoATI/ACI treatment outside Australia, given the need for a dedicated Lab. How much capital would be required to set up operations overseas. Might the company look to strike licence deals of some sort.
Stem Cell Therapy advancements, page-465
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
63.5¢ |
Change
0.005(0.79%) |
Mkt cap ! $151.8M | |||
| Open | High | Low | Value | Volume |
| 64.0¢ | 64.0¢ | 63.0¢ | $156.2K | 246.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 38222 | 62.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 64.0¢ | 29000 | 2 |
View Market Depth
| Last trade - 15.54pm 19/11/2024 (20 minute delay) ? |
| OCC (ASX) Chart |